Kornimate/medical-research-clean huggingface dataset:
autologous immune enhancement therapy (aiet) for cancer patients

Conditions: Patients With Cancer

Summary: this is a retrospective study that included 60 cancer patients who underwent autologous nk cell and cd8 t cell therapy between january 2016 and december 2021

the dysfunction and reduced proliferation of peripheral immune cells including cd8 t and nk cells have been observed in both aging and cancer patients, thereby challenging the immune cell therapy in these subjects. therefore, we evaluated the growth of these lymphocytes in elderly patients with several types of cancer and the correlation of peripheral blood (pb) indexes to the expansions. this is a retrospective study that included 60 cancer patients who underwent autologous nk cell and cd8 t cell therapy between january 2016 and december 2021. by optimizing the antiviral and tumor surveillance ability of both nk cells and ctls through serial steps from isolation and expansion, followed by re-infusion of these activated cells back to the patient body, aiet has become a promising, cutting-edge method in detecting and eliminating cancer cells. the study aimed to evaluate the safety and effectiveness of 60 cancer patientsreceiving aiet.

Eligibility criteria:
inclusion criteria: * patients aged 18 - 75 * patients have been diagnosed with cancer. * patients signed the written informed consent form. exclusion criteria: * severe health conditions such as serious infection, autoimmune diseases, or using any anti-rejection drugs
transversus abdominis plane block versus wound infiltration for postcesarean analgesia

Conditions: Postcesarean Analgesia

Summary: the study will compare the analgesic efficacy of transversus abdominis plane block and wound infiltration in parturients undergoing cesarean delivery under spinal anesthesia.

this randomized, controlled, double-blind study will be conducted on asa physical status ii parturients with full-term singleton pregnancy undergoing elective cesarean delivery under spinal anesthesia. patients will receive either ultrasound-guided transversus abdominis plane block or wound infiltration at the end of surgery. after delivery, all patients will receive standard analgesia (intravenous ketorolac and oral paracetamol) and patient-controlled analgesia with intravenous fentanyl. total fentanyl consumption at 24 h, pain scores at 2, 4, 6, 12, and 24 h, side effects, and patient satisfaction will be compared between the 2 groups.

Eligibility criteria:
inclusion criteria: 1. american society of anesthesiologists physical status ii 2. full-term singleton pregnancy exclusion criteria: 1. age \ 40 years 2. height \<150 cm 3. weight \<60 kg 4. body mass index ≥40 kg/m2 5. contraindications to spinal anesthesia (patient refusal, increased intracranial tension, coagulopathy, uncorrected hypovolemia) 6. hypersensitivity to any of the drugs used in the study 7. significant cardiovascular, renal, or hepatic disease 8. known fetal abnormalities 9. emergency situations
observational study to evaluate the actual use and effectiveness of dymista® nasal spray in asian patients

Conditions: Allergic Rhinitis

Summary: gathering knowledge on the use of dymista® in asian patients who receive dymista® for the first time in routine clinical practice

a) primary objective: gathering knowledge on the use of dymista® in asian patients who receive dymista® for the first time in routine clinical practice; patient's demographic; anamnestic background including: * allergic and other comorbidities * allergic conjunctivitis * polysensitization * current symptoms * previous treatments of allergic rhinitis * usage of current asthma reliever medication * family history of allergy b) secondary objective: * response to therapy with dymista® nasal spray in routine clinical practice. * quality of sleep (by vas) * troublesomeness in daily activities (by vas) * patient's assessment about the regular use of dymista® * patients opinion about continuation of dymista® treatment after end of the observational period

Eligibility criteria:
inclusion criteria: * the first prescription of dymista® nasal spray according to the summary of product characteristics (spc) and patient information leaflet and independently from the patient's enrollment in the study. * patients with moderate to severe seasonal or perennial allergic rhinitis * for hong kong and malaysia: adult and children of age ≥ 12 years * for taiwan: adult and children of age ≥ 6 years. * for thailand: adults and children of age ≥ 12 years with seasonal and/or perennial allergic rhinitis or children of age 6-11 years with only seasonal allergic rhinitis * acute allergic rhinitis symptoms at the day of inclusion (i.e. vas-score ≥50 mm) * signed informed consent/assent from the patient and, if applicable, the parent(s) or legal guardian(s) in compliance with local requirements. * ability to understand and follow the instructions for using dymista® nasal spray according to the patient information leaflet. * willingness to complete and return the patient card. exclusion criteria: * vas score \<50 mm on day of inclusion * known allergic reaction from and/or intolerance to dymista® nasal spray or any of the ingredients. * pregnancy/planned pregnancy or breastfeeding during this nis * patients or parent(s)/legal guardians (as applicable) not able to fulfill study requirements according to the investigator's opinion.
fall prevention in a geriatric nursing home setting using the music of nolwenn leroy

Conditions: Ataxia

Summary: falls are the largest cause of death in the elderly and those with dementia have even a higher incidence of falling. the purpose of this study is to determine whether listening to the music of nolwenn leroy is effective in fall prevention in those elderly patients who are residents in a geriatric nursing home facility. the music of nolwenn leroy has been shown to be effective in fall reduction in a different setting (posturographic changes and fall prevention associated with music therapy: the nolwenn effect (usa clinicaltrials.gov identifier: nct00121693) )with results better than listening to mozart of any other music.

falls are a serious health issue and are the greatest cause of death in the elderly. the use of the music of nolwenn leroy in fall prevention has been reported at a major scientific meeting posturographic changes and fall prevention associated with music therapy: the nolwenn effect (usa clinicaltrials.gov identifier: nct00121693) featured at the 7th annual american music therapy association conference in orlando, florida, nov 15-20, 2005 and is in publication in the indexed literature. decreasing falls in a geriatric nursing home setting is associated with the saving of lives. we propose the utilization of the nolwenn effect in our resident geriatric population and comparing fall rates to those we have carefully recorded in the past. daily listening to selections from nolwenn leroy's cd "nolwenn" have been played for one month in the community gathering areas of our fourth floor dementia unit in the morning for approximately 5-10 minutes. this unit has an increased rate of falls due to the characteristics of its residents and our one month retrospective study has demonstrated a statistical reduction in the rate of falls subsequent to the daily listening of nolwenn leroy music. we propose to expand the listening of music to the entire building and study the nolwenn effect on the fall rate of all residents over the calendar year 2006. preliminary observations have been associated with a decrease rate of falls on our dementia floor when compared to our previous fall rates. our nursing staff is well trained in fall reporting and will continue to do so in the manner previously established before implementation of this study. this study is dependant upon the utilization of fall statistics previously established at our institution. the incorporation of these statistics will allow us to demonstrate a cost effective method of reducing falls that might save lives, evoke societal change and act as a model for other geriatric nursing home settings.

Eligibility criteria:
inclusion criteria: * full time resident in geriatric facility exclusion criteria: * all others

Keywords: fall prevention, music therapy, geriatric, nursing home
proteomic analysis on myopic children using orthokeratology lenses with good or poor myopic control

Conditions: Myopia; Healthy; Orthokeratology

Summary: the key objective of the study is to gain an understanding of the biochemical processes that contribute to orthokeratology lenses being more effective in specific individuals compared to others. with this knowledge, we hope to optimize treatment effectiveness in those currently experiencing less favorable outcomes from treatment in the future. the primary aim is to investigate differences in protein levels in children using orthokeratology lenses with various effects of myopia control. hypothesis: there is a significant difference in the expression of molecules in children with various effects of myopia control.


Eligibility criteria:
inclusion criteria: * children treated with orthokeratology lenses. * children on or above the 95th percentile of myopia growth curves for european children at the time of treatment initiation. * treatment and follow-up duration ≥ 6 months. exclusion criteria: * current use of eye drops. * objective signs of dry eyes on slit-lamp examination. * active eye infection.
study of t cells targeting cd19/bcma (cart-19/bcma) for high risk multiple myeloma followed with auto-hsct

Conditions: Safety and Efficacy

Summary: cart therapy has showed good safety and efficacy in treatment of lymphoma and acute lymphoblastic leukemia. researchers want to see if this helps people with high risk multiple myeloma after auto-hsct.to test the safety and efficacy of giving targeting cd19 and bcma t cells in treating high risk multiple myeloma followed with auto-hsct.

adults ages 18-75 with high risk multiple myelomas (r-iss iii stage or with extramedullary infiltration or with del(17p), t(4;14), t(14;16), t(14;20), 1q21+ or disease progression during treatment). design: participants may be screened with: medical history physical exam blood and urine tests heart tests bone marrow sample multiple scans and x-rays participants will have apheresis. blood is removed through a needle in an arm. t cells are removed. the rest of the blood is returned through a needle in the other arm. the cells will be changed in a laboratory. participants will get auto-hsct. hematopoietic reconstitution after auto-hsct, participants will get the t cells through the iv within 3 days. maintenance therapy with imids was received after combined car t infusion. after this, participants will stay in the hospital for at least 9 days and stay nearby for 2 weeks. then they will have blood tests and see a doctor. participants will visit the clinic 1, 2, 3, 6, 9 and 12 months after the infusion, then every 3 months until disease progression. a bone marrow sample will be taken at the 3-month visit.

Eligibility criteria:
inclusion criteria: * multiple myeloma patients eligible for auto-hsct. * high risk multiple myeloma (r-iss iii stage or with extramedullary infiltration or with del(17p), t(4;14), t(14;16), t(14;20), 1q21+ or disease progression during treatment). * expected survival ≥ 3 months. * creatinine \< 2.0 mg/dl. * blood coagulation function: pt and aptt \<2x normal. * arterial blood oxygen saturation\>92%. * alt(alanine aminotransferase)/ast (aspartate aminotransferase)\< 3x normal * karnofsky scores ≥ 60 and ecog score≤2. * adequate venous access for apheresis, and no other contraindications for leukapheresis. * patients should not take immunotherapy in three months prior to cart cells infusion. * voluntary informed consent is given. exclusion criteria: * pregnant or lactating women. * uncontrolled active infection. * active hepatitis b or hepatitis c infection. * concurrent use of systemic steroids. recent or current use of inhaled steroids is not exclusionary. * previously treatment with any gene therapy products. * any uncontrolled active medical disorder that would preclude participation as outlined. * hiv infection. * history of myocardial infarction and severe arrhythmia in half a year. * any form of primary immunodeficiency (such as severe combined immunodeficiency disease). * patients with fever of unknown origin (t\>38℃).
neuro-orthopedic registry of the university hospital of toulouse

Conditions: Neurologic Disorder

Summary: neuro-orthopedics corresponds to the evaluation and therapeutic management of the orthopedic consequences of damage to the central or peripheral nervous system. in case of neurological impairment, there may be joint, motor, sensory and cognitive impairments that limit the patient's activities. the management of these orthopedic problems falls within the specific framework of neuro-orthopedics because in the presence of neurological, problems are different and more complex than in classical orthopedics. in this context, a well-conducted evaluation is a prerequisite for appropriate treatment.


Eligibility criteria:
inclusion criteria: patient with a neurological condition that benefits: * an injection of botulinum toxin in the context of spasticity : about 20 / week * pre or post-therapeutic clinical evaluation (botulinum toxin or surgery): approximately 10 / week * clinical or instrumental evaluation of the walking or upper limb (physiological functional explorations): about 10 / week * a medical and surgical multidisciplinary consultation about spasticity : about 15 / month * a discussion during neuroorthopedic multidisciplinary consultation meeting about the patient's file and anomalies of walking: about 8 / month * implementation of a baclofen pump (neurosurgery): about 2 / month * functional surgery of the upper or lower limb (locomotor institute, orthopedic surgery and traumatology): about 4 / sem exclusion criteria: patient (or the legal representative) who opposes the data collection.

Keywords: neuro-orthopedics register
evaluation of an e-tool designed to facilitate communication between allophone patients and pediatricians in emergency departments.

Conditions: Language Barrier

Summary: in france, over 21 million people visit emergency departments every year, 10% of whom speak little or no french. the language barrier is a problem for patient safety and quality of care. ethical and financial aspects are also affected. unnecessary tests are more frequent, hospital stays more numerous and longer. patient's management may be inappropriate. patients are less satisfied, understand and adhere less to cmanagement and recommendations. some solutions are available to the emergency physician, but their contribution is limited. a professional interpreter is reliable and takes cultural aspects into account, but his or her cost is high and availability incompatible with emergency care. translation by a close relative poses the problem of confidentiality. telephone interpreting is available at any time, but is expensive and less satisfying than direct interaction. computerized machine translation is economical and easy to access, but does not take into account all medical terms. it also poses a data protection problem. phraselators translate predefined phrases with precision, but are time-consuming and unsophisticated. in addition, these aids are used during the consultation. they are therefore difficult to combine and take up care time. this care time is mainly devoted to establishing medical history essential for the diagnosis, prognosis and treatment decisions. marti is a digital tool for pediatric emergency room consultations. its aim is to enable the emergency physician to start the consultation with a medical history completed autonomously by the parents during their waiting time. its content has been developed by emergency physicians. language and cultural barriers are overcome through the use of simple phrases and pictograms developed with linguists, language schools and immigrant organizations. marti was used in a pediatric emergency department. feedback from patients and carers indicates that it is ready to be tested in real-life conditions. this pilot study is designed to evaluate how marti improves communication with an allophone or a person with comprehension difficulties, according to the emergency physician in charge of the consultation.


Eligibility criteria:
inclusion criteria: * adult * person responsible for a child admitted to pediatric emergency. * person with a language barrier. * person speaking one of the 11 languages proposed by marti. * signed informed consent indicating that the subject has understood the purpose and procedures of the study and agrees to participate in the study and to abide by the requirements and restrictions inherent in the study. * affiliation with a health insurance exclusion criteria: * person who shares a common language with the physician. * illiterate person. * person accompanying a child with a life-threatening emergency. * subject without health insurance. * pregnant women. * subject in the exclusion period of another study or in the "national volunteer file".
a trial investigating the efficacy and safety of insulin detemir versus insulin nph in combination with metformin and diet/exercise in children and adolescents with type 2 diabetes insufficiently controlled on metformin with or without other oral antidiabetic drug(s) with or without basal insulin

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted globally. the aim of the trial is to investigate the efficacy and safety of insulin detemir versus insulin neutral protamine hagedorn (nph) in combination with the maximum tolerated dose of metformin and diet/exercise on glycaemic control in children and adolescents with type 2 diabetes insufficiently controlled on the maximum tolerated dose of metformin with or without other oral antidiabetic drug(s) with or without basal insulin.


Eligibility criteria:
inclusion criteria: * informed consent from the subject or a legally acceptable representative (lar) and child assent from the subject obtained before any trial-related activities.trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial * male or female, above or equal to 10 years and below or equal to 17 years at the time of signing informed consent/assent * diagnosis of type 2 diabetes mellitus at least 3 months prior to screening * treated with the maximum tolerated stable dose of metformin for at least 3 months prior to screening or have documented complete metformin intolerance * hba1c (glycosylated haemoglobin) above or equal to 7.0% and below or equal to 10.5% (above or equal to 53 mmol/mol and below or equal to 91 mmol/mol) at screening exclusion criteria: * maturity onset diabetes of the young (mody) * fasting c-peptide at screening below 0.6 ng/ml * impaired liver function defined as alanine aminotransferase (alt) above or equal to 2.5 times upper normal limit * known proliferative retinopathy or maculopathy requiring acute treatment as judged by the investigator * treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 3 months before the day of screening
butyrophilins role in colon cancer

Conditions: Colonic Cancer

Summary: quantification of btnl molecules in colon cancer in order to determinate if their could be used as a prognostic marquer


Eligibility criteria:
inclusion criteria: * patient is older than 18 years old, * signed participation consent, * non-metastatic colon cancer immediately resectable or metastatic and liver synchronous for which it was decided a combined colic and liver surgery (metastatic patient at the outset) in multidisciplinary consultation meeting. * performance status (ps) 0 or 1 * affiliated to the social security or beneficiary exclusion criteria: * rectal cancer, colon cancer recurrence * emergency of colon cancer surgery * history of inflammatory disease of the digestive tract (crohn's disease or ulcerative colitis) * patient who received neoadjuvant therapy other than chemotherapy * patient treated with immune-suppressors or long-course corticosteroids \<12 months * pregnant women or likely to be pregnant (without effective contraception) or breastfeeding, * person in urgent situation, person under legal protection measure, or unable to express his / her consent, * impossibility of submitting to the medical examination of the test for geographical, social or psychological reasons
a study to investigate the effect of pd-217,014 on abdominal pain/discomfort in patients with ibs.

Conditions: Irritable Bowel Syndrome

Summary: the purpose of this study is to determine the effectiveness of pd-217,014 in the treatment of abdominal pain/discomfort associated with irritable bowel disease.


Eligibility criteria:
inclusion criteria: * males and females having irritable bowel syndrome as defined by the rome ii criteria. * patients must have had normal examination of colon anatomy within the last 5 years exclusion criteria: * patient with an organic gastrointestinal disease. * patients with poor renal function. * patients with severe constipation.
utilization of the oncocee™ platform to evaluate selected biomarker alterations in ctcs isolated from patients with mbc

Conditions: Metastatic Breast Cancer

Summary: this study evaluates the performance of a blood test for detecting biomarkers in metastatic breast cancer patients at one clinic against standard testing.

the primary objective of this pilot study is to detect the expression of fgfr1 and ar on circulating tumor cells (ctcs) isolated from the peripheral blood of metastatic breast cancer (mbc) patients using the oncocee™ platform. no procedures will be associated with this study, as these mutations will be evaluated from the leftover blood that has already been sent for standard of care er and her2 using the same platform. results from this testing will be correlated with results obtained from standard testing to calculate the rate of concordance between tests.

Eligibility criteria:
inclusion criteria: * current patient at participating clinic * metastatic breast cancer diagnosis * 18 years of age or older exclusion criteria: none